Vaccines:

Indications for: PENTACEL

Active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age (prior to 5th birthday).

Clinical Trials:

Immune responses to Pentacel were evaluated in four US studies: Studies 494-01, P3T06, 494-03, and M5A10. In Study M5A10, participants were randomly assigned to receive Pentacel or separately administered Daptacel, IPOL, and ActHIB at 2, 4, and 6 months of age. Pentacel or Control vaccines were concomitantly administered with 7-valent pneumococcal conjugate (PCV7, Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age, and Hepatitis B vaccine (Merck and Co. or GlaxoSmithKline Biologicals) at 2 and 6 months of age. 

 

Diphtheria and Tetanus

  • The proportions of participants achieving diphtheria antitoxin and tetanus antitoxoid seroprotective levels 1 month following three and four doses of Pentacel or Daptacel (+ IPOL + ActHIB) in Study P3T06 were as followed, respectively:

    • Post-Dose 3

      • Diphtheria Antitoxin (% ≥0.01 IU/mL): 100% for Pentacel vs 100% for Daptacel

      • Tetanus Antitoxoid (% ≥0.10 IU/mL): 99.7% for Pentacel vs 100% for Daptacel

    • Post-Dose 4

      • Diphtheria Antitoxin (% ≥0.10 IU/mL): 100% for Pentacel vs 100% for Daptacel

      • Tetanus Antitoxoid (% ≥0.10 IU/mL): 100% for Pentacel vs 100% for Daptacel

Pertussis

  • Sweden I Efficacy Trial

    • A randomized, double-blinded, placebo-controlled study was conducted in Sweden during 1992-1995 (Sweden I Efficacy Trial) under the sponsorship of the National Institute of Allergy and Infectious Diseases.

    • 2587 infants received Daptacel and 2574 infants received a non-US licensed DT vaccine as placebo at 2, 4, and 6 months of age. The mean length of follow-up was 2 years after the third dose of vaccine.

    • The protective efficacy of Daptacel was 84.9% (95% CI, 80.1-88.6) against pertussis after 3 doses using the WHO case definition (≥21 consecutive days of paroxysmal cough with culture or serologic confirmation or epidemiologic link to a confirmed case).

    • The protective efficacy of Daptacel was 77.9% (95% CI, 72.6-82.2) against mild pertussis (≥1 day of cough with laboratory confirmation).

    • Daptacel demonstrated to sustain protection against pertussis for the 2-year follow-up period.

  • Serology Bridging Analysis

    • Immune responses to FHA, PRN, and FIM in a subset of infants who received 3 doses of Daptacel in the Sweden I Efficacy Trial were compared to the Post-Dose 3 and Post-Dose 4 responses in a subset of US children from Study 494-01 who received Pentacel.

    • The noninferiority criteria were met for seroconversion rates for anti-FHA and anti-FIM after Dose 4 of Pentacel compared to Dose 3 of Daptacel. The noninferiority criteria was not met for seroconversion for anti-PRN.

    • The noninferiority criteria were met for GMCs for anti-FHA, anti-PRN, and anti-FIM after Dose 4 of Pentacel compared to Dose 3 of Daptacel. 

  • Study P3T06

    • US infants were randomly asigned to receive either Pentacel or Daptacel + IPOL + ActHIB at 2, 4, 6, and 15–16 months of age.

    • The noninferiority criteria were met for seroconversion rates and GMCs for each of the pertussis antigens after Dose 3 of Pentacel compared with Dose 3 of Daptacel. 

    • The noninferiority criteria were met for all comparisons after Dose 4 of Pentacel compared with Dose 4 of Daptacel, except for anti-PRN GMCs.

  • Study 006

    • US infants were randomly assigned to receive 3 doses of Vaxelis at 2, 4, and 6 months of age and Pentacel at 15 months of age, or control group vaccines (4 doses of Pentacel + Recombivax HB). All patients received concomitant Prevnar 13 at 2, 4, 6, and 15 months of age.

    • The noninferiority criteria for antibody vaccine response rates and GMCs for all pertussis antigens were met after the 4th dose except for GMCs for PRN.

Poliomyelitis

  • Study P3T06

    • Infants were randomly assigned to receive the first 3 doses of Pentacel or Daptacel + IPOL + ActHIB at 2, 4, and 6 months of age, one month after the third dose of study vaccines.

    • More than 99.4% of patients in both groups achieved neutralizing antibody levels of ≥1:8 for Poliovirus types 1, 2, and 3.

  • Study 494-01

    • Infants were randomly assigned to receive Pentacel or HCPDT + POLIOVAX + ActHIB.

    • GMTs of antibodies to Poliovirus types 1, 2, and 3 one month after Dose 4 of Pentacel were 2304, 4178, and 4415, respectively, and one month following Dose 4 of POLIOVAX were 2330, 2840, and 3300, respectively.

Invasive Disease due to H. Influenzae Type b

  • Study 494-01

    • Pentacel did not meet the noninferiority criteria for the proportion of patients who achieved an anti-PRP level ≥1.0 mcg/mL and for anti-PRP GMCs compared with separately administered ActHIB.

  • Studies P3T06 and M5A10

    • Pentacel met the noninferiority criteria for the proportion of patient who achieved an anti-PRP level ≥1.0 mcg/mL compared with separately administered ActHIB.

  • Study M5A10

    • Pentacel met the noninferiority criteria for anti-PRP GMCs compared with separately administered ActHIB.

  • Study 494-01

    • At 15 months of age before receiving Dose 4 of study vaccines, 68.6% of Pentacel recipients (N = 829) and 80.8% of separately administered ActHIB recipients (N = 276) had an anti-PRP level ≥0.15 mcg/mL.

    • After Dose 4, 98.2% of Pentacel recipients (N = 874) and 99.0% of separately administered ActHIB recipients (N = 291) had an anti-PRP level ≥1.0 mcg/mL. 

  • Study P3T06

    • At 15 months of age before receiving Dose 4 of study vaccines, 65.4% of Pentacel recipients (N = 335) and 60.7% of separately administered ActHIB recipients (N = 323) had an anti-PRP level ≥0.15 mcg/mL. 

    • Following Dose 4 of study vaccines, 97.8% of Pentacel recipients (N = 361) and 95.9% of separately administered ActHIB recipients (N = 340) had an anti-PRP level ≥1.0 mcg/mL.

Adult Dosage:

Not recommended.

Children Dosage:

Each dose is 0.5mL IM, in anterolateral thigh (infants) or deltoid muscle. Give as a 4 dose series at 2 months, 4 months, 6 months, and 15–18 months of age. May give 1st dose as early as 6 weeks of age. Previously vaccinated with ≥1 dose of Daptacel, IPV, or Hib conjugate vaccine: Pentacel may be used to complete vaccination series; see full labeling. May give other vaccines concurrently (use separate inj site).

PENTACEL Contraindications:

Anaphylaxis associated with any previous dose or component. Encephalopathy within 7 days of a previous dose of a pertussis-containing vaccine. Progressive neurological disorder (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy).

PENTACEL Warnings/Precautions:

Fever (≥105°F within 48hrs), persistent inconsolable crying (lasting ≥3hrs within 48hrs), shock (within 48hrs), seizure (within 3 days), or Guillain-Barre syndrome (within 6 weeks) of previous tetanus toxoid vaccine. Seizure risk (may pretreat with antipyretics, eg, acetaminophen). May defer in acute febrile illness. Have epinephrine inj (1:1000) available. Immune deficiency. Pregnancy (Cat.C): not recommended.

PENTACEL Classification:

DTaP + IPV + Hib/PRP-T.

PENTACEL Interactions:

Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.

Adverse Reactions:

Local reactions: inj site erythema, swelling, tenderness. Systemic reactions: fever, crying, fussiness.

Note:

Report adverse events to VAERS at (800) 822-7967 and to Sanofi Pasteur at (800) 822-2463.

Generic Drug Availability:

NO

How Supplied:

Doses—5 (2 vials/dose)